Oana Farcau

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Is portal vein thrombosis more than a clot?

In CLEARED, PVT carried higher 30-day mortality despite lower MELD-Na. This editorial argues PVT reflects structural disease of the portal vein, which may explain why anticoagulation often disappoints.

https://t.co/QkJOiXD0FN

#LiverX

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Does response to terlipressin in LT candidates matter beyond HRS-AKI itself? This review examines when its use helps, when it may harm, and how treatment response may affect MELD-based prioritization.

@KavishPatidar11 @Pummy92 @NBegumOzturkMD @Ouranos_Kon
https://t.co/vc5HzZPSBK

[Laia Aceituno @laiaaas]

🔥 ICI is a safe option to downstage/bridge to transplantation.

We present our results at #GIASCO, a hot topic in HCC, thank you to everyone who stopped by!!

Thank you to the @AEEHLiver for the support #award

More to come soon!!

[Arndt Vogel @ArndtVogel]

🔥off the press:
The use of immunotherapy pre-liver transplant
@JHepatology
https://t.co/ozppHjFIyh
👉Hepatology Snapshot
👉Our thoughts on the use of ICI before liver transplant in HCC
👉Food for thoughts..
@myESMO @EASLedu @ILCAnews #livertwitter

[Rautou Pierre-Emmanuel @RautouE]

Hepato-pulmonary syndrome (HPS) in 196 patients with PSVD:
▶️prevalence: 7%
▶️risk factors: telomere biology disorders &
less preserved liver function
▶️outcome similar to PSVD patients w/o HPS when applying HPS MELD exception policy for transplantation
https://t.co/zKj9xjyneL

[Evangelos Triantafyllou @TriantafyllouE_]

Pleased to share our @NatRevGastroHep review (w/ @CathrinLC and @LuciaPossamai ) on immune-mediated liver injury from checkpoint inhibitors | @ImperialMDR @IHepatology | #cancer #immunotherapy #liver #inflammation #livertwitter

https://t.co/Undaore0YJ

[Jose Ignacio (Iñaki) Fortea @JIFortea]

🚨 It is finally here‼️

📜 Carvedilol vs. Propranolol for preventing decompensation and mortality in compensated & decompensated cirrhosis

📎 https://t.co/kt0v8wz9et

🫂 Huge thanks to all coauthors! 🙌

[Maxime Ronot @maximeronot]

🚨EASL CPG on the management of HCC in @JHepatology
Major update!

✅ LI-RADS endorsed
✅ Refined treatment algo
✅ More evidence supporting locoregional treatments
✅ Up-to-date discussions

👉https://t.co/Co4RkGuC1k

[massimo iavarone @massimoiava]

Histological predictors of aggressive recurrence* of HCC after liver resection - Journal of Hepatology https://t.co/KelAbCP1F9
*defined as those exceeding the Milan criteria at first recurrence
@BCLC_group @Alexfornergon @ma5RN @bruixj @MarcoSanduzzi @ezemauro_ok

[JHEP Reports @JHEP_Reports]

Liver resection and transplantation in the era of checkpoint inhibitors

🔓#OpenAccess at👉https://t.co/IaFAWSfKUS

#LiverTwitter
@MSHSSurgery

[jaumebosch @jaumebosch9]

Mechanisms and implications of recompensation in cirrhosis - JHEP Reports
✅ Curious about current thoughts on Recompensation of Cirrhosis?
➡️ Proud to share with you our recent publication in cooperation with Salvatore Piano and Thomas Reiberger. https://t.co/QWznV0b1Hc

[Riad Salem @riadsalemIR]

Y90 RADSEG now #1 bridging treatment in US ahead of TACE, ablation and EBRT @JVIRmedia @allisonkwong @DanSzeMDPhD @SIRspecialists @cirsesociety @ASTSChimera @AASLDtweets @EASLnews @_ILTS_ @AST_info @ASTRO_org @ACRORadOnc @NorthwesternIR @NorthwesternMed
https://t.co/qV328UNiXN

[HEPATOLOGY Journal @HEP_Journal]

ORIGINAL ARTICLE

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized-trial

Alvarado-Tapias et al.
#LiverX
https://t.co/159Yqgotyp

[Thomas Reiberger @ReibergerThomas]

#LiverX
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder (#PSVD) & cirrhosis (#ACLD)

🟢 taurocholic acid (AUROC 0.899)

📕@JHEP_Reports
by @GeorgSemmler @xander_petrenko @BernharScheiner @jcgarciapagan

🔗https://t.co/46gyDZxf27

[Aleksander Krag @AleksanderKrag]

Just released - check out EASL‘s new guideline hot of the press on liver transplantation! 👇👇
A clinically focused guidance, a must read for all hepatologists!
@DebbieShawcros1 @ThomasBerg24

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New @TheLancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial)

https://t.co/05kYRbhSBK

#CRCSM #LiverTwitter

[Vienna Liver News @ViennaLiverNews]

🚨📔Publication alert: Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome https://t.co/LqStK7zgPI

[Mattias Mandorfer @MattiasMandorf1]

It's out: The standard reference on
🩸portal vein thrombosis🩸
👉 diagnosis
👉 management
👉 endpoints for future clinical studies
Chapeau @RautouE & team
🔗 https://t.co/1PsJP2YtYX
#LiverTwitter @LancetGastroHep

[Dominik Bettenworth @BettenworthDb]

This work took 3⃣ years from conception to publication in @NatureRevGastro
‘A global consensus on definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice’
Essentials on this challenging #IBD treatment situation in a 🧵

1/11

[Hepatology Communications @HepCommJournal]

📑 Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death
#LiverTwitter #OpenAccess

https://t.co/kx6EGXShXo